EGFR and breast neoplasm: This class of agents might be useful in the treatment of HER2- and EGFR-dependent breast tumors and may be effective for the treatment of cancers that have acquired resistance to monoclonal antibodies or tyrosine kinase inhibitors targeting these enzymes.